PUS1 and metastatic prostate carcinoma: Collectively, these results suggest that targeting PUS1 with Mogroside IV-E may represent a promising therapeutic strategy for metastatic prostate cancer, as it not only inhibits tumor cell migration and invasion but also improves survival outcomes in xenograft mice.